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CD-31Background: Thromboxane synthase (TXS) metabolizes prostaglandin H2 into thromboxanes, which are biolog-
ically active on cancer cells. TXS over-expression has been reported in a range of cancers, and associated with
angiogenesis and poor outcome. TXS has been identiﬁed as a potential therapeutic target in NSCLC. This study
examines a link between TXS expression, angiogenesis, and survival inNSCLC.Methods: TXS andVEGFmetabolite
levels were measured in NSCLC serum samples (n = 46) by EIA. TXB2 levels were correlated with VEGF. A 204-
patient TMAwas stained for TXS, VEGF, and CD-31 expression. Expression was correlatedwith a range of clinical
parameters, including overall survival. TXS expression was correlated with VEGF and CD-31. Stable TXS
clones were generated and the effect of overexpression on tumor growth and angiogenesis markers was
examined in-vitro and in-vivo (xenograft mouse model). Results: Serum TXB2 levels were correlated with VEGF
(p b 0.05). TXS and VEGF were expressed to a varying degree in NSCLC tissue. TXS was associated with VEGF
(p b 0.0001) and microvessel density (CD-31; p b 0.05). TXS and VEGF expression levels were higher in adeno-
carcinoma (p b 0.0001) and female patients (p b 0.05). Stable overexpression of TXS increased VEGF secretion in-
vitro. While no signiﬁcant association with patient survival was observed for either TXS or VEGF in our patient
cohort, TXS overexpression signiﬁcantly (p b 0.05) increased tumor growth in-vivo. TXS overexpression was
also associated with higher levels of VEGF, microvessel density, and reduced apoptosis in xenograft tumors.
Conclusion: TXS promotes tumor growth in-vivo in NSCLC, an effect which is at least partly mediated through
increased tumor angiogenesis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Lung cancer is the leading cause of cancer related death in the devel-
opedworld, accounting for 12% of deathsworldwide [1]. Median surviv-
al for themajority of patients with advanced non-small cell lung cancer
(NSCLC) is 18 months and 9 months for locally advanced or metastatic
disease respectively [2]. Current therapeutic strategies are relatively in-
effective, which are reﬂected by an overall survival rate of just 15% [3].
Non-small cell lung cancer (NSCLC) is among the most common cause
of cancer-related deaths in men and women, and comprises approxi-
mately 80–85% of all lung cancers [4].; AA, arachidonic acid; COX,
2, thromboxane A2; TXB2,
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ights reserved.Angiogenesis is vital to tumor growth andmetastasis. Previous stud-
ies have demonstrated that angiogenesis (assessed bymicrovessel den-
sity) is one of themost important prognostic factors in resectable NSCLC
[5]. It is necessary for the supply of oxygen and nutrients to tumors
N2 mm in diameter, and is therefore essential for successful tumor
growth [6]. In order to grow and metastasize, solid tumors secrete a
range of pro-angiogenic factors, which tip the delicate balance in favor
of angiogenesis [7]. Angiogenesis targeting agents were among the
ﬁrst to be uncovered as having potential beneﬁt in NSCLC. They are
often used as treatment for NSCLC, while their biomarkers are currently
being assessed as predictors of response. VEGF is one of themost specif-
ic and crucial regulators of angiogenesis, with a number of studies dem-
onstrating an association with both microvessel density and a poor
prognosis in NSCLC [8–11]. However, the complex process of angiogen-
esis is also controlled by a large number of other factors including the
vascular endothelial growth factor receptors (VEGFRs), the plasmino-
gen activators (PAs), the matrix metalloproteinases (MMPs) and their
inhibitors (MMPIs), basic ﬁbroblast growth factor (bFGF), transforming
growth factor-beta (TFG-β), and platelet-derived growth factor (PDGF),
among others.
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by cyclooxygenase (COX), lipoxygenase (LOX), or epoxygenase (cyto-
chrome P-450) enzyme pathways. The cyclooxygenase enzymes
(COX-1 and COX-2) catalyze the ﬁrst step in the generation of
downstream prostanoids from arachidonic acid [12]. COX-derived
prostanoids are involved in a wide range of physiological processes,
but have also been implicated in a range of disease states, such as arthri-
tis, heart disease, and pulmonary hypertension [13]. In the past number
of years, there has been signiﬁcant interest in the role of COX-2 in
cancer development and progression. Expression of this enzyme has
been associated with a poor prognosis in lung cancer [14–16], while a
potential role for COX-2 in lung cancer chemoprevention has been
investigated in a number of clinical trials [17–19]. However, chronic
administration of high concentrations of selective COX-2 inhibitors
has been associated with an increased risk of adverse cardiovascular
events [20–22]. Recent studies suggest that the tumor–promoting
effects of COX-2 over-expression may be attributable to downstream
products of AA metabolism. Increased COX-2 expression is associated
with increased levels of downstream enzymes required for prostanoid
synthesis, such as prostaglandin E2 synthase (PGE-S), prostaglandin
D2 synthase (PGD-S), and thromboxane A2 synthase [23]. However,
the relationship of prostanoid proﬁle to cancer growth is not fully
understood.
Thromboxane synthase (TXS) activitywasﬁrst described in platelets
[24]. TXS metabolizes the cyclooxygenase product, prostaglandin H2,
into thromboxanes, which are biologically active on cancer cells. TXA2
is a potent vasoconstrictor and bronchoconstrictor, as well as a potent
promoter of platelet aggregation [25,26]. TXS and its product, TXA2,
have been shown to promote proliferation, invasion, metastasis, and
angiogenesis in a variety of cancers [27–31]. TXS over-expression has
been reported in thyroid, prostate, colorectal, bladder, andmore recent-
ly, lung cancer [27–29,31–33]. Over-expression of this enzyme has been
associated with a signiﬁcant reduction in survival in bladder cancer
patients [28], although this observation does not seem to transfer to
other cancer types [33]. This enzyme pathway has also been closely
linked with angiogenesis [30,34], suggesting a mechanism for its effects
on tumor growth. Gene transfer of TXS signiﬁcantly increased tumor
growth in a murine colon-cancer model, an effect mediated in part
through an induction of tumor angiogenesis [35]. Furthermore, TXA2
acted as a potent stimulator of angiogenesis, both directly, and by induc-
ing VEGF (vascular endothelial growth factor) and PDGF (platelet-de-
rived growth factor) secretion from platelets following aggregation
[36,37].
A previous study carried out in our lab examined the expression pro-
ﬁle and role of thromboxane synthase in NSCLC, and demonstrated its
potential as a therapeutic target in the disease [33]. The precise mecha-
nisms underlying these anti-tumor effects are unclear, although an anti-
angiogenic mechanism has been previously suggested. While TXS has
been associated with tumor angiogenesis in colorectal cancer, this has
not been fully investigated in NSCLC. The aim of this studywas to exam-
ine a link between TXS expression and tumor angiogenesis using both
retrospective patient analysis and an in-vivo xenograft model.
2. Materials and methods
2.1. Patient and tumor specimens
For generation of a NSCLC tissue microarray (TMA), parafﬁn blocks
from 204 patients who underwent chemotherapy with surgical resec-
tion at St. James's Hospital (2000–2005) for NSCLC of varying histology,
stage, and grade were collected. Patients who underwent pre-operative
chemotherapy, or were found to have stage IV disease were excluded.
Patient tumors were staged according to the tumor-node-metastasis
(TNM) classiﬁcation and histologically classiﬁed according to the
World Health Organization guidelines. The NSCLC tissue samples were
classiﬁed as 1) adenocarcinoma, 2) squamous cell carcinoma, and 3)others. Patients range in age from 41 years to 86 years. Patients were
followed up by the tumor registries for survival time and outcome
with median follow-up of 60 months (ranging from 1 to 88 months).
2.2. Generation of NSCLC tissue microarrays
Tissue microarrays were assembled using a tissue arraying
instrument (Beecher Instruments, Silver Spring, MD). Corresponding
H and E slides for each patient were marked for viable areas of tumor
by a pathologist. A 2 mm diameter stylet was used for sampling, with
three replicate core samples of tumor taken from different regions in
each donor block to account for tumor heterogeneity. Four μM sec-
tions of the resulting microarray blocks were cut on a microtome
(Leica Microsystems Inc., IL, USA) and dried onto poly-L-lysine-coat-
ed glass slides (BDH Laboratory Supplies, Poole, England).
2.3. Immunohistochemical staining
TXS, VEGF, and CD-31 staining of both NSCLC TMAs and mouse
xenograft tissue was carried out using a Dako (Glostrup, Denmark)
Autostainer Universal Staining System with a 1:150 dilution of a TXS
primary antibody (CaymanChemical), a 1:500 dilution of a VEGF prima-
ry antibody (Millipore), a 1:100 dilution of a CD-31 antibody (Dako,
Glostrup, Denmark), and a 1:500 dilution of a PCNA antibody
(Abcam). Xenograft staining for apoptosis was carried out using an
ApopTag® Apoptosis Detection Kit (Millipore). Staining was carried
out according to manufacturers' instructions. Stained sections were
scanned using a ScanScope GL digital slide scanner and Aperio
ImageScope software (Aperio Technologies Inc., CA, USA).
2.4. Quantiﬁcation of staining intensity
TXS, VEGF, and CD-31 staining in NSCLC tissue micro-array tissue
was blindly scored and quantiﬁed by three independent observers
(M.C.C., K.G. and G.P.). TXS and VEGF expression levelswithin tumor tis-
sue were quantiﬁed across three representative cores per patient as a
product of the staining intensity (0= negative, 1= weak, 2= moder-
ate, 3= strong) × percentage cells stained (b25%, b50%, b75%, b100%).
Staining intensitywasquantiﬁed under highmagniﬁcation (×20), using
an Aperio Image Scope and corresponding imaging software (Aperio
Technologies). CD-31 microvessel density quantiﬁcation was carried
out by manually counting the number of vessels in each representative
TMA core under ×20magniﬁcation, with the average number of vessels
then calculated for each patient. TXS and VEGF expression patterns
were correlated with a range of clinical parameters such as patient
demographics (gender), tumor classiﬁcations (tumor subtype, stage,
grade, and nodal status), and overall survival. Both TXS and VEGF
were also correlated with vessel count (as assessed by CD-31 staining).
CD-31 is a commonly used stain for assessment of angiogenesis by
micro-vessel density analysis and has been previously used for vessel
quantiﬁcation in both TMA [38] and xenograft studies [35].
2.5. Enzyme immunoassay analysis of metabolite generation
Serum levels of TXB2 (thromboxane A2 metabolite) and VEGF were
measured in a retrospective panel of NSCLC patient samples (n = 46
patients). Any patients with a history of aspirin or NSAID use were
removed from the study. Serum samples were isolated from whole
blood (placed into Clot Activator serum collection tubes) by centrifuga-
tion at 3000 ×g at 4 °C for 10min. Enzyme immunoassay kitswere used
to determine both TXB2 (Assay Designs, MI, USA) and corresponding
VEGF (Quantikine human VEGF immunoassay; R and D systems) levels
in serum isolated from NSCLC patients. The same kits were also used to
determine TXB2 and VEGF levels in cell culture supernatants of TXS
overexpressing clones and corresponding controls. The assayswere car-
ried out according to manufacturers' instructions.
Fig. 1. Correlation of TXB2 levels with those of VEGF in NSCLC patient serum samples
(n = 46).
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The SKMES-1 (squamous cell carcinoma) NSCLC cell line was obtain-
ed from the American Type Culture Collection (Rockville, MD, USA). Cells
were maintained in a humidiﬁed atmosphere of 5% CO2 in air at 37 °C.
SKMES-1 cells were maintained in Modiﬁed Eagle's Medium + Earle's
medium (MEM), supplemented with 10% (v/v) FBS, penicillin
streptomycin, L-glutamine, and non-essential amino acids. Subculturing
was carried out when the cells reached 80% conﬂuency.
Female 6–8 week old BALB/c nude mice were obtained from Harlan
Laboraties, UK, housed at a constant temperature and suppliedwith lab-
oratory chow and water ad libitum on a 12-hour dark/light cycle. Surgi-
cal procedures and care of animals were approved by the Ethics
Committee of Trinity College Dublin, Ireland, and were carried out
according to institutional guidelines. All experiments were carried out
under a license granted by the Department of Health and Children in
Ireland (Ref: B100/3506).
2.7. Generation and characterization of stable transfectant clones
Human TXAS cDNA was a gift from Prof. Kenneth V. Honn (Wayne
State University, Detroit, MA, USA). A 1.5 Kb DNA fragment containing
the entire TXAS coding sequencewas digested frompBluescript plasmid
DNA and inserted into the site of the mammalian vector pcDNA3.1(−)
(Invitrogen Corporation, CA, USA) to generate pcDNA3.1(−)-TXAS.
Subsequent transfection and characterization experiments are as previ-
ously described by Cathcart et al., 2011 [33].
2.8. In-vivo tumor growth assay
Wild-type, pcDNA 3.1(−) and thromboxane synthase overexpress-
ing SKMES-1 cells (3 × 106) were administered subcutaneously into
the left dorsal ﬂank of 6–8 week-old female nude mice (BALB/c).
When tumor size reached approximately 50mm3, tumor sizewasmea-
sured twiceweekly using a digital caliper. Tumor volumewas calculated
from size measurements using the formula V= width × length ×Π/6.
Experiments were terminated when tumors reached a size of
1500 mm3, and the animals were sacriﬁced by cervical dislocation.
Tumors were then isolated and excised, processed, and embedded in
parafﬁn for histological analysis. 5 μM tissue sections were cut onto
glass slides for immunohistochemical staining, as outlined above.
2.9. Statistical analysis
Correlation analysis of expression levels of these enzymes was car-
ried out using the Pearson correlation coefﬁcients, with a p b 0.05
taken as signiﬁcant. Association between clinicopathological features
and expression of these enzymes was assessed using an unpaired
Student's t-test or a Mann–Whitney U test for continuous data, where
appropriate. Overall survival was examined using Kaplan–Meier's sur-
vival curves, with differences in survival assessed by the log-rank test.
Results are expressed as mean ± SEM, with data taken as signiﬁcant
where p b 0.05. All statistical analyses were carried out using InStat
Statistical Software Package version 3.0 with survival analysis carried
out using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. VEGF and thromboxane B2 metabolite levels in NSCLC serum samples
TXB2 and VEGFmetabolite levels weremeasured in a panel of NSCLC
serum samples (n = 46) by ELISA. Thromboxane B2 levels were signif-
icantly (p b 0.05) associated with those of VEGF levels in the same
NSCLC patients (Pearson r = 0.4; Fig. 1).3.2. Tissue microarray analysis of thromboxane synthase and VEGF in
NSCLC: association and correlation with clinical parameters
A204-patientNSCLC tissuemicroarray generatedusingpatients pre-
senting to St. James's Hospital, Dublin, was stained for TXS, VEGF, and
CD-31 expression. While quantiﬁcation and analysis of TXS expression
in these patients have previously been published [33], it's link to VEGF
expression and angiogenesis in our dataset is unknown. Both TXS and
VEGF were expressed to a varying degree in NSCLC tissue (Fig. 2).
Expression levels were signiﬁcantly higher in adenocarcinoma patients,
relative to squamous for both TXS (120 ± 7 units adenocarcinoma
vs. 58.9 ± 5.5 units squamous, p b 0.0001; Fig. 3A) and VEGF (205 ±
9.1 units adenocarcinoma vs. 150 ± 8 units squamous; p b 0.001;
Fig. 3B) proteins. Levels were also higher in female patients, relative
to males for both TXS (98.6 ± 8.4 units female vs. 82 ± 5.4
units male, p b 0.05; Fig. 3C) and VEGF (188.4 ± 10.4 units female vs.
169± 7.1 units male, p=0.1; Fig. 3D). No associationwith nodal status
was observed for either protein, although VEGF levels were signiﬁcantly
(p b 0.05) higher in late stage tumors (200± 9.6 units stage 3 vs. 155±
13.3 units stage 2). No difference in either TXS or VEGF expression was
observed for patientswho smoked, relative to those that did not (90±8
units smokers vs. 73 ± 8.2 units non-smokers TXS; 180 ± 9.8 units
smokers vs. 178± 6.6 units non-smokers VEGF). High VEGF expression
has largely been associated with a poor prognosis in lung cancer [39].
However, neither VEGF nor TXS [33] were signiﬁcantly associated
with survival in our patient cohort, either alone or combined
(Table 1). Our data suggests that while TXS is signiﬁcantly associated
with expression of the potent angiogenic factor, VEGF, neither of these
factors are prognostic in NSCLC.3.3. Association of both thromboxane synthase and VEGFwith angiogenesis
(microvessel density) analysis in NSCLC tissue microarrays
To assess a potential link of thromboxane synthase expression levels
with markers of angiogenesis, TXS levels in TMAs were correlated with
both VEGF and microvessel density (CD-31). While VEGF is a potent
angiogenic factor, consistently associated with tumor angiogenesis,
microvessel density (MVD) is often assessed as a determinant of in-
vivo angiogenic activity [40,41]. As observed in patient serum, TXS tis-
sue expression levels were extremely signiﬁcantly (p b 0.0001) corre-
lated with those of VEGF, suggesting a link between these two
proteins (Pearson r = 0.43; Fig. 4A). TMAs were stained for CD-31 as
a marker of angiogenesis and to correlate with thromboxane synthase
expression (Fig. 4B). TXS was weakly (p b 0.05) correlated with vessel
count (Pearson r = 0.2; Fig. 5C), as determined by CD-31 staining
Fig. 2. Immunohistochemical staining for TXS [33] and VEGF in NSCLC tissue micro-arrays (TMAs). Expression of both proteins was mainly localized to tumor epithelial cells, although
expression was also detected in smooth muscle (weak) and also in endothelial cells of the tumor-associated vasculature (moderate). 10× magniﬁcation.
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VEGF expression and microvessel density was also observed in this pa-
tient cohort (Pearson r = 0.22; Fig. 4D).
3.4. Stable over-expression of thromboxane synthase in SKMES-1 cells
Stable clones over-expressing TXS were previously generated and
characterized in NSCLC SKMES-1 cells [33]. These stable TXS over-Fig. 3.Quantiﬁcation of TXS and VEGF staining inNSCLC TMAs. A) TXS expression andNSCLC tum
D) VEGF expression and gender. Data is expressed as mean ± SEM (* p b 0.05, ** p b 0.001, ***expressing clones (and corresponding controls)were assessed for levels
of TXS and VEGF protein andmetabolites (in cell culture supernates) by
western analysis and enzyme immunoassay (EIA) respectively. VEGF
levels (protein and metabolite) were higher in the TXS overexpressing
clones relative to corresponding controls (data not shown). Further-
more, TXB2 metabolite levels were extremely signiﬁcantly (p b 0.001)
associated with those of VEGF (Pearson r= 0.96; data not shown), pro-
viding further evidence for a link between TXS and VEGF expression.or subtypes B)VEGF expression andNSCLC tumor subtypes C) TXS expression and gender
p b 0.0001).
Table 1
Expression proﬁle of TXS [33] and VEGF inNSCLC tissuemicro-arrays (n=204 patients). TXS and VEGF staining inNSCLC TMAswas quantiﬁed and associatedwith patient demographics,
clinical parameters, and overall survival.
Patient demographic TXS staining intensity (mean ± SEM units) p-Value VE GF staining intensity (mean ± SEM units) p-Value
Gender
(n = 124) male 81,9 ± 3.4 0.04 168.8 ± 7.1 0J06
(n = 73) female 98.6 ± 9.6 188.44 = 10.3
Tumor subtype
(n = 83) adenocarcinoma 119 ± 7 b011001 205.2 ± 9 b0.0001
(n = 92) squamous cell carcinoma 58.9 ± 5.5 150 ± 7.9
Tumor stage
(n = 105) stage 1 93.3 ± 7.5 0.7 73.4 ± 8.2 0.006
(n = 43) stage 2 82.7 ± 9.3 78.8 ± 13.2
(n = 43) stage 3 90 ± 9.7 55.3 ± 9.6
Tumor grade
(n = 13) grade 1 104.7 ± 21.7 0.02 196 ± 32.4 0.09
(n = 106) grade 98 ± 6.4 grade 2 vs. grade 3 185.34 = 7.7 grade 2 vs. grade 3
2 (n = 64) grade 3 70.4 ± 6.7 165.5 ± 10.1
Nodal status
(n = 119) node negative 91.74:6.3 0.4 173.6 ± 7.6 0.7
(n = 79) node positive 83.2 ± 7.1 178.349.7
Overall survival (months)
(n = 88) b median value 52.2 ± 3.7 months 0.32 57.8 ± 3.2 months 0.19
(n = 89) N median value 58.5 ± 3.6 months 52.8 ± 3.8 months
Combined VE GF & TXS overall survival (months)
(n = 56) low TXS and low VE GF 53.74:4.7 months 0.06 N/A N/A
(n = 33) high TXS and high VE GF 46.6 ± 6 months
(n = 15) high TXS and low VEGF 30 ± 6.2 months
(n = 35) high TXS and high VE GF 53 ± 5.6 months
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angiogenesis in-vivo
Previous studies carried out in our group have demonstrated that
TXS overexpression in SKMES-1 cells signiﬁcantly increased tumor cell
growth in-vitro. However, cell growth rate in-vitro does not predictFig. 4. Correlation of TXS TMA staining with markers of angiogenesis. A) TXS/VEGF correlation
VEGF/CD-31 correlation. All correlations were assessed using the Pearson coefﬁcient.the tumor growth rate in-vivo, which is also affected by host factors of
the tumor microenvironment, such as migration of endothelial cells
into the tumors to generate blood vessels. To determine if similar effects
of TXS overexpression on tumor growth would be observed in-vivo,
overexpressing SKMES-1 cells were subcutaneously injected into the
hind ﬂanks of female nude mice. While the cells were initially slow to. B) CD-31 expression in NSCLC TMAs (20× magniﬁcation). C) TXS/CD-31 correlation D)
Fig. 5. The effect of TXS overexpression on tumor growth in-vivo (mouse xenograft
model). Tumor growth was assessed using digital calipers. Data is expressed as mean ±
SEM (n = 10/group; *p b 0.05).
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cantly faster rate than wild-type or empty vector (pcDNA 3.1(−)) con-
trol tumors (which did not seed in the majority of animals) (p b 0.05;
n = 10/group; Fig. 5). Immunohistochemical staining of the resultant
tumors revealed increased expression of TXS protein in tissue from
the stable TXS clones (Fig. 6A), conﬁrming that the increased tumor
growth in this group was mediated through TXS overexpression. The
effect of TXS overexpression on tumor growth in-vivomay bemediated
through effects on tumor angiogenesis. Indeed, TXS has been associated
withVEGF expression in a number of studies [27,30,42,43]. In this study,
immunohistochemical expression of VEGF was higher in TXS overex-
pressing xenograft tissue, relative to wild-type (Fig. 6), conﬁrming pre-
vious observations.
We have previously demonstrated that the pro-tumor effects of TXS
overexpression are mediated in part through a protective effect on
tumor cell apoptosis [33]. In this study, apoptosis levels were greater
in the xenograft tissue of wild-type clones, relative to that of TXS
overexpresing clones (Fig. 7), supporting an anti-apoptotic role for
TXS overexpression in-vivo. We did not detect major differences in
PCNA expression between TXS clones and wild-type. However, greater
microvessel density (as assessed by CD-31 staining) was observed in
TXS clones, relative to wild-type controls (Fig. 7).Fig. 6. Immunohistochemical staining of mouse xenograft tumors for TXS and VEGF4. Discussion
The tumor-promoting effects of COX-2 overexpression may be
attributable to speciﬁc downstreamproducts of arachidonic acidmetab-
olism [44]. The function of thromboxane synthase and its prostanoid,
thromboxane A2 in the cardiovascular system has been extensively
studied and is well known. The enzyme plays a major role in maintain-
ing cardiovascular hemostasis, through its effects on platelet activation
and aggregation. The impact of thromboxane synthase on cancer devel-
opment and progression has received considerable interest over the
past number of years. Expression of this enzymehas been shown to pro-
mote tumorigenesis via its effects on tumor growth and metastasis
[27–29,31]. A link between thromboxane pathway activation and
angiogenesis has also been demonstrated in-vitro [30,42] and in-vivo
[30,35]. A recent study carried out in our lab has identiﬁed a role for
TXS in NSCLC, suggesting its potential as a therapeutic target in the dis-
ease. Its association with both physiological and pathological angiogen-
esis implicates this pathway in its pro-tumor effects. An association of
the prostaglandin biosynthetic pathway with angiogenesis has previ-
ously been identiﬁed in NSCLC patient biopsies [43]. However, the link
between TXS and in-vivo tumor angiogenesis has not yet been investi-
gated. This study aimed to determine the link between TXS expression
and angiogenesis in NSCLC patient blood and tissue samples and to
assess the role of TXS expression in NSCLC growth and angiogenesis
in-vivo.
There is strong evidence for a role for TXS in physiological angiogen-
esis. TXS inhibitors strongly inhibited capillary tube formation in human
vascular endothelial cells [45]. Pharmacological inhibition of COX-2
inhibited TXA2 generation, endothelial cell migration, and ﬁbroblast
growth factor-induced corneal angiogenesis. Both of these parameters
were also inhibited by treatment with a TP antagonist. U-46619, a TP
agonist was shown to restore both migration and angiogenesis
responses invoked by COX-2 inhibition [34]. We have previously dem-
onstrated that levels of the circulating TXS metabolite, TXB2 are signiﬁ-
cantly higher in plasma samples fromNSCLC patient samples, relative to
cancer-free controls, an effect which may potentially impact on a
patient's risk of developing venous thrombosis [33]. In the current
study, levels of both the TXB2 metabolite and VEGF were measured in
serum from NSCLC patients (also indicative of circulating TXS and
VEGF levels). Circulating TXB2 levels were signiﬁcantly correlated with
those of VEGF, suggesting a linkwith angiogenicmechanisms. Similarly,
when NSCLC tissuemicroarrays were assessed for expression proﬁles ofexpression. Placental tissue was used as a staining control. 10× magniﬁcation.
Fig. 7. Immunohistochemical staining of mouse xenograft tumors for markers of proliferation (PCNA), angiogenesis (microvessel density; CD-31), and apoptosis (ApopTag®).
Representative negative controls are shown for both PCNA and CD-31 staining. A kit positive control is shown for the ApopTag staining due to the very weak nature of the counter-
stain. 10× magniﬁcation.
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to note that in our previous studywe observed a highly signiﬁcant asso-
ciation of COX-2 with TXS expression [33]. As thromboxane A2, the
prostanoid product of TXS, has also been shown to mediate COX-2
dependant angiogenesis [29], the current observations suggest a role
for VEGF in this COX-2 mediated effect. While a link between the pros-
taglandin pathway and angiogenesis has previously been identiﬁed in
NSCLC biopsies [43], our study is the ﬁrst demonstration of a link
between the thromboxane pathway and angiogenesis markers in both
resected tumor tissue and matching blood samples.
Further TMA analysis revealed that both TXS and VEGF expression
levels were signiﬁcantly higher in adenocarcinoma patients, relative to
squamous. The signiﬁcance of these observations is unclear, but it has
been observed that patients with adenocarcinoma are at a higher risk
of developing venous thrombosis than those with squamous cell carci-
noma [46]. Increased VEGF expression has previously been reported in
adenocarcinoma, relative to squamous cell carcinoma in NSCLC [47].
Furthermore, a recent study by Pajares et al., demonstrated that higher
VEGF, VEGFR1, and VEGFR2 expression corresponded with a reduced
risk of disease progression in early squamous cell carcinoma (but not
adenocarcinoma), suggesting that VEGF behaves differently between
the two histologies [48]. An increase in both TXS and VEGF expression
was also observed in female patients, relative to males, although
this did not reach statistical signiﬁcance for VEGF expression. It is
unclear why these expression patterns would be increased in female
patients. Previous studies have demonstrated that estrogen contributed
to the increased TXA2 in a murine model, suggesting a hormonal inﬂu-
ence here [49], While these ﬁndings have been previously reported for
TXS [33], the current study demonstrates that VEGF expression levels
follow a similar pattern in the same patient cohort.
Expression levels of both enzymes were unaffected by nodal status,
with only VEGF showing increased expression in late stage patients.Interestingly, both VEGF and TXS expression levels appeared to be
lower in grade 3 tumors, relative to grade 2 (although this was only sig-
niﬁcant for TXS). These observationswith TXS are in contrast to those in
a prostate cancer study [29], but are supported byprevious observations
in breast cancer [50], suggesting that the expression pattern of this
enzyme may vary between cancer types. No difference in either TXS
or VEGF expression was observed in patients that smoked, compared
to non-smokers. This observation is surprising, given ﬁnding of other
studies [51,52]. Previous studies, which have investigated this link
have been predominantly carried out in experimental models of ciga-
rette smoke-induced carcinogenesis. Huang et al., recently noted
increased TXS expression in NSCLC smokers, relative to non-smokers
[51,52]. However, the signiﬁcant discrepancies in sample sizes between
their studies (n= 37) and ours (204-patient TMA) suggest that further
investigation is required.
In contrast to some other studies, no signiﬁcant correlation of
TXS expression with patient survival was observed, even when TXS
expression was examined in combination with levels of VEGF expres-
sion. While this observation may seem surprising, given previous ﬁnd-
ings, similar observations have been observed in breast cancer
patients where low levels of TXS expression were correlated with
tumors of high grade and a predicted poor clinical outcome [50]. The
authors also found that levels of the thromboxane receptor (TP) were
negatively associated with disease-free survival, suggesting that the
downstream receptor, as opposed to its corresponding synthase, may
be prognostic in the disease [53]. It is also interesting to note that
VEGF was not signiﬁcantly associated with overall survival in our
patient cohort, although a trend was observed.
We have previously identiﬁed tumor cell apoptosis as a mechanism
underlying the effects of TXS inhibition in NSCLC [33]. While there is
increasing evidence demonstrating that TXS inhibition induced apopto-
sis inNSCLC [54], TXS and its product, TXA2, have also been implicated in
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[35], migration [28,29], invasion, and tumor cell metastasis [30]. In the
current study, TXS expression was strongly associated with VEGF in
patient TMAs, while a weak association with microvessel density (CD-
31 expression) was also observed. CD-31 has previously been used as
a marker of MVD in TMA-based studies [38] and has also been used as
an angiogenesis marker in-vivo xenograft studies [35]. In this study,
VEGF expression levels were higher in TXS overexpressing clones, with
VEGF levels also strongly associated with TXB2 in culture supernates
from stable cells. This supports previous ﬁndings of increased VEGF
secretion following TP activation in lung cancer cells and suggests a
link with tumor angiogenesis [42].
Injection of TXSoverexpressing SKMES-1 cells into athymic nudemice
resulted in a signiﬁcant increase in tumor growth, relative to empty vec-
tor or wild-type controls. Our observations are in agreement with previ-
ous observations in a xenograft colorectal cancer model [35], and
suggest that TXS is a potential therapeutic target in NSCLC pathogenesis.
They also support the ﬁndings of Wei et al., who demonstrated that A-
549 cells with TP overexpression induced greater tumor growth in-vivo
[42]. Histological examination of tumor tissue from our xenografts
revealed increased TXS, VEGF, and CD-31 expression in TXS overexpress-
ing clones, conﬁrming the ﬁndings of both patient and cell-line studies.
The co-expression of TXS and VEGF may enhance neovascularization in
NSCLC tissue. The mechanisms underlying this link are unknown,
although ERK induction as well as the upstream kinases of PKA, EGFR
kinase. and Src kinase have been implicated in the TP-mediated induction
of VEGF expression in NSCLC [42]. While the study byWei et al., is one of
the only ones to examine a link between the thromboxane receptor and
tumor angiogenesis, the role of TP in tumor development and progression
has gained considerable interest in recent years [55]. Apoptosis analysis
also revealed a protective effect against tumor cell apoptosis in-vivo,
conﬁrming previously published observations [33]. Levels of the prolifer-
ation marker, PCNA did not appear to be signiﬁcantly altered between
wild-type and overexpressing TXS tissue. While our observations are
purely qualitative, they suggest that the effects of TXS overexpression
on in-vivo tumor growth are regulated via increased angiogenesis as
well as dysregulation of the apoptotic/mitotic index.
The association of VEGF and TXS expression observed in this study
indicates activation of the coagulation cascade in addition to angiogen-
esis, an effect which has been previously demonstrated in renal cell car-
cinoma [56]. Indeed, the increased risk of thrombotic events in patients
treatedwith bevacizumab highlights the importance of concurrent anti-
coagulation therapy in ‘at risk’ patients [57–59]. The association of TXS
with angiogenesis in NSCLC was further conﬁrmed by correlation with
CD-31 (a marker of microvessel density) in the same TMAs. While
microvessel density studies are best conducted in full-face sections as
opposed to TMA cores, we did not assess patient survival with this
marker, but merely aimed to correlate TXS expression with MVD in
the same samples. Similar associations between MVD and molecular
markers have been made in previously published TMA-based studies,
supporting our experimental approach [38,40,60].
In conclusion, this study conﬁrms previous observations of the role
of TXS in NSCLC using an in-vivo model, providing further support for
the potential of TXS inhibition as a therapeutic strategy in the disease.
An underlying mechanism was identiﬁed through positive correlation
of TXS expression with markers of angiogenesis both in-vitro and in-
vivo, providing clear evidence that these pro-tumor effects are at least
partly mediated through increased angiogenesis. While neither TXS
nor VEGF were found to be prognostic in our patient cohort, this study
suggests that the combined use of a VEGF and a TXS inhibitor may be
an alternative approach to VEGF targeting alone for the treatment of
NSCLC.
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